- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT05076864
Levosimendans Pharmacokinetics in Intensive Care Patients. An Observational Study. (LEFKIP)
Levosimendans Pharmacokinetics in Intensive Care Patients
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Aims: To gain a better understanding of the pharmacokinetics of Levosimendan in critically ill patients and in particular in those patients with and without renal failure and in those receiving CRRT. This project may give a better basis to determine whether dose monitoring and adjustment of Levosimendan is necessary to avoid toxicity or under treatment. In order to study Levosimendan pharmacokinetics, the Karolinska laboratory has in parallel developed a method for analysis of the substance and its metabolites.
Research questions:
- To what extent are Levosimendan and its active metabolites dialysable in patients receiving continuous renal replacement therapy.
- How do the concentrations of Levosimendan and its active metabolites differ in critically ill patients with and without acute renal failure?
Method:
The is a prospective observational study conducted on adult intensive care units at Karolinska University Hospital.
Study Population: Critical care patients who due to clinical need are prescribed Levosimendan by treating physician will be included into one of three groups based on degree of AKI (KDIGO classification) and need for CRRT. This is a non-interventional study.
Number of patients to be included: we intend to include 4-12 patients per group.
Procedure: The decision to prescribe Levosimendan will be made by treating physicians as will decisions regarding dose, dose adjustment and length of treatment.
Screening for inclusion will occur when a decision to prescribe Levosimendan has been made.
Samples of blood, urine and ultrafiltration fluid from the CRRT circuit are to be analysed to determine concentration of Levosimendan and its metabolites. Plasma concentrations will be obtained, before and after the dialysis filter.
Concentration monitoring will occur over a period of up to 6 days, with test taken at 0, 6 and 20 hours after infusion start and after cessation of Levosimendan every two hours for the first 10 hours and there after twice a day for the next 5 days. A maximum of 30 samples (15 in non CRRT patients) of 1-3ml are taken.
Patient groups:
Group 1: Levosimendan + no AKI or KDIGO AKI stage 1. Group 2: Levosimendan + KDIGO AKI stage 2-3, not CRRT Group 3: Levosimendan + KDIGO AKI stage 1-3 with CRRT.
Analysis:
Analysis of the plasma concentration of Levosimendan and its metabolites (OR-1896, OR-1855) is performed at the clinical pharmacology department, Karolinska University Hospital. Reference substances have been provided by Orion Pharma.
Definitions:
Acute Kidney Failure (AKI) is defined according to the KDIGO definition: Creatinine entry from the baseline (percentage increase) and volume of urine production or CRRT treatment.
Type d'étude
Inscription (Anticipé)
Contacts et emplacements
Coordonnées de l'étude
- Nom: Claire Rimes-Stigare, MD, PhD
- Numéro de téléphone: 004651770000
- E-mail: claire.rimes-stigare@regionstockholm.se
Sauvegarde des contacts de l'étude
- Nom: Susanne Rysz, MD, PhD
- Numéro de téléphone: 004651770000
- E-mail: susanne.rysz@regionstockholm.se
Lieux d'étude
-
-
-
Stockholm, Suède
- Recrutement
- Karolinska University Hospital
-
Contact:
- Claire Rimes-Stigare, MD, PhD
- Numéro de téléphone: 004651770000
- E-mail: claire.rimes-stigare@regionstockholm.se
-
Contact:
- Susanne, MD
- Numéro de téléphone: 004651770000
- E-mail: sussanne.rysz@regionstockholm.se
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
Intensive Care Unit patients in whom the treating physician has decided due to clinical indication to administer levosimendan. Dose and length of treatment decided by treating physician.
With Group 1: No renal failure or Acute Kidney Injury(AKI)* stage 1. Group 2: AKI stage 2-3, not receiving renal replacement therapy. Group 3: Receiving continuous renal replacement therapy (CRRT)
*AKI classification system Kidney Disease Improving Global outcomes (KDIGO)
La description
Inclusion Criteria:
° Adult Intensive care patients in whom treating physicians have judged to be in need of Levosimendan treatment.
Exclusion Criteria:
- Patient <18 years of age
- Pregnancy
- Patients receiving Intermittent hemodialysis
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Concentration of levosimendan and OR 1896 1855 in plasma
Délai: 1-5 days
|
Plasma concentrations of levosimendan and its active metabolites afte Levosimendan infusion.
|
1-5 days
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Anticipé)
Achèvement de l'étude (Anticipé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 4-1951/2021
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
produit fabriqué et exporté des États-Unis.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .